Literature DB >> 11683675

Platelet-derived growth factor receptors expressed in response to injury of differentiated vascular smooth muscle in vitro: effects on Ca2+ and growth signals.

A Lindqvist1, B O Nilsson, E Ekblad, P Hellstrand.   

Abstract

Vascular smooth muscle cells (VSMCs) in the intact vascular wall are differentiated for contraction, whereas the response to vascular injury involves transition towards a synthetic phenotype, with increased tendency for proliferation. Platelet-derived growth factor (PDGF) is thought to be important for this process. We investigated expression and functional coupling of PDGF receptors (PDGFRs) alpha and beta in rat tail arterial rings kept in organ culture, in order to capture early events in the phenotypic transition. In freshly dissected rings no PDGFR immunoreactivity was found in medial VSMCs, whereas PDGFR alpha was detected in nerve fibres. After organ culture for 1-4 days PDGFR alpha and beta as well as phospholipase Cgamma2 (PLCgamma2), known to couple to PDGFR, were expressed in VSMCs within 100 microm of the cut ends. Calponin, a marker for the contractile phenotype, was decreased near the injured area, suggesting that cells were in transition towards synthetic phenotype. In these cells, which showed functional Ca2+-release from the sarcoplasmic reticulum, PDGF-AB (100 ng x mL(-1)) had no effect on [Ca2+]i, whereas cultured VSMCs obtained from explants of rat tail arterial rings responded to PDGF-AB with an increase in [Ca2+]i. However, PDGFR within the cultured rings coupled to growth signalling pathways, as PDGF-AB caused a tyrphostin AG1295-sensitive activation of extracellular signal-regulated kinases 1 and 2 and of [3H]-thymidine incorporation. Thus, early expression of PDGFR in VSMC adjacent to sites of vascular injury coincides with signs of dedifferentiation. These receptors couple to growth signalling, but do not activate intracellular Ca2+ release.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683675     DOI: 10.1046/j.1365-201X.2001.00873.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  7 in total

Review 1.  Loss of CREB regulation of vascular smooth muscle cell quiescence in diabetes.

Authors:  Jane E B Reusch; Peter A Watson
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  MEF2 is regulated by CaMKIIδ2 and a HDAC4-HDAC5 heterodimer in vascular smooth muscle cells.

Authors:  Roman Ginnan; Li Yan Sun; John J Schwarz; Harold A Singer
Journal:  Biochem J       Date:  2012-05-15       Impact factor: 3.857

3.  Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes.

Authors:  Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Mong-Heng Wang; Adviye Ergul
Journal:  J Pharmacol Exp Ther       Date:  2008-10-21       Impact factor: 4.030

4.  Overexpression of C‑sis inhibits H2O2‑induced Buffalo rat liver cell apoptosis in vitro and alleviates liver injury in a rat model of fulminant hepatic failure.

Authors:  Hao Ding; Zhili Wen
Journal:  Int J Mol Med       Date:  2018-05-17       Impact factor: 4.101

Review 5.  Plant-Derived Products for Treatment of Vascular Intima Hyperplasia Selectively Inhibit Vascular Smooth Muscle Cell Functions.

Authors:  Kang Xu; Mohanad Kh Al-Ani; Xin Pan; Qingjia Chi; Nianguo Dong; Xuefeng Qiu
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-11       Impact factor: 2.629

6.  Modulation of Vascular Smooth Muscle Cell Phenotype by High Mobility Group AT-Hook 1.

Authors:  Yoojin Jung; Hae Sun Lee; Jung Min Ha; Seo Yeon Jin; Hye Jin Kum; Farzaneh Vafaeinik; Hong Koo Ha; Sang Heon Song; Chi Dae Kim; Sun Sik Bae
Journal:  J Lipid Atheroscler       Date:  2021-01-13

7.  Molecular Action of Hydroxytyrosol in Attenuation of Intimal Hyperplasia: A Scoping Review.

Authors:  Ubashini Vijakumaran; Muhammad Dain Yazid; Ruszymah Bt Hj Idrus; Mohd Ramzisham Abdul Rahman; Nadiah Sulaiman
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.